GlaxoSmithKline PLC banner

GlaxoSmithKline PLC
NYSE:GSK

Watchlist Manager
GlaxoSmithKline PLC Logo
GlaxoSmithKline PLC
NYSE:GSK
Watchlist
Price: 51.295 USD 1.09%
Market Cap: $104.6B

Wall St Price Targets

GSK Price Targets Summary
GlaxoSmithKline PLC

Wall Street analysts forecast GSK stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for GSK is 57.079 USD with a low forecast of 39.205 USD and a high forecast of 77.034 USD.

Lowest Forecast
Price Target
39.205 USD
24% Downside
Average Forecast
Price Target
57.079 USD
11% Upside
Highest Forecast
Price Target
77.034 USD
50% Upside
GlaxoSmithKline PLC Competitors:
Price Targets
LMB
Limbach Holdings Inc
68% Upside
BTDR
Bitdeer Technologies Group
98% Upside

Revenue
Forecast

2% / Year
Past Growth
3% / Year
Estimated Growth
Estimates Accuracy
-3%
Average Miss
2% / Year
Past Growth
3% / Year
Estimated Growth
Estimates Accuracy
-3%
Average Miss

Over the last 13 years, the compound annual growth rate for Revenue has been 2%. The projected CAGR for the next 8 years is 3%.

Gross Profit
Forecast

2% / Year
Past Growth
3% / Year
Estimated Growth
Estimates Accuracy
-5%
Average Miss
2% / Year
Past Growth
3% / Year
Estimated Growth
Estimates Accuracy
-5%
Average Miss

Over the last 13 years, the compound annual growth rate for Gross Profit has been 2%. The projected CAGR for the next 8 years is 3%.

Operating Income
Forecast

2% / Year
Past Growth
4% / Year
Estimated Growth
Estimates Accuracy
-6%
Average Miss
2% / Year
Past Growth
4% / Year
Estimated Growth
Estimates Accuracy
-6%
Average Miss

Over the last 13 years, the compound annual growth rate for Operating Income has been 2%. The projected CAGR for the next 8 years is 4%.

Pre-Tax Income
Forecast

1% / Year
Past Growth
14% / Year
Estimated Growth
Estimates Accuracy
-31%
Average Miss
1% / Year
Past Growth
14% / Year
Estimated Growth
Estimates Accuracy
-31%
Average Miss

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 1%. The projected CAGR for the next 3 years is 14%.

Net Income
Forecast

2% / Year
Past Growth
6% / Year
Estimated Growth
Estimates Accuracy
-21%
Average Miss
2% / Year
Past Growth
6% / Year
Estimated Growth
Estimates Accuracy
-21%
Average Miss

Over the last 13 years, the compound annual growth rate for Net Income has been 2%. The projected CAGR for the next 8 years is 6%.

Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is GSK's stock price target?
Price Target
57.079 USD

According to Wall Street analysts, the average 1-year price target for GSK is 57.079 USD with a low forecast of 39.205 USD and a high forecast of 77.034 USD.

What is the Revenue forecast for GlaxoSmithKline PLC?
Projected CAGR
3%

Over the last 13 years, the compound annual growth rate for Revenue has been 2%. The projected CAGR for the next 8 years is 3%.

What is the Gross Profit forecast for GlaxoSmithKline PLC?
Projected CAGR
3%

Over the last 13 years, the compound annual growth rate for Gross Profit has been 2%. The projected CAGR for the next 8 years is 3%.

What is the Operating Income forecast for GlaxoSmithKline PLC?
Projected CAGR
4%

Over the last 13 years, the compound annual growth rate for Operating Income has been 2%. The projected CAGR for the next 8 years is 4%.

What is the Pre-Tax Income forecast for GlaxoSmithKline PLC?
Projected CAGR
14%

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 1%. The projected CAGR for the next 3 years is 14%.

What is the Net Income forecast for GlaxoSmithKline PLC?
Projected CAGR
6%

Over the last 13 years, the compound annual growth rate for Net Income has been 2%. The projected CAGR for the next 8 years is 6%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett